4-1 | I saw something new in Baghdad recently. At one of the city’s many checkpoints, men in white coats and N95 masks were standing in front of the soldiers, checking whether passengers in minivans were wearing their masks. The cigarette vendors that wind their way through the waiting cars had added a sideline in selling surgical masks.
4-1 | Up until March 2021, Papua New Guinea had been largely spared of any major COVID-19 outbreak. Within a few weeks, confirmed COVID-19 cases have tripled and increasing numbers of healthcare staff are testing positive, pushing them into home quarantine. The health system in Papua New Guinea is at risk of collapsing as health facilities managing COVID-19 are close to capacity and almost too stretched to provide regular primary healthcare.
3-24 | Since February, another heavy wave of COVID-19 has swept through the West Bank. Over 20,000 patients are currently being treated for COVID-19. This has added further pressure to an already fragile healthcare system, leaving medical staff struggling to provide adequate care to a soaring number of patients. Both the Government of Israel and the Palestinian Authorities must immediately, as a matter of the utmost priority, significantly increase efforts to slow the spread of COVID-19 and its new variants.
3-10 | MSF International President appeals to governments stonewalling on landmark proposal Geneva, 9 March 2021—As governments prepare to meet for another round of talks at the World Trade Organization (WTO) tomorrow, Médecins Sans Frontières/Doctors Without Borders (MSF) urged the small number of governments that continue to block a landmark waiver on intellectual property (IP) during the pandemic to immediately reverse their stonewalling and allow formal negotiations at the WTO to start.
2-26 | The US Food and Drug Administration (FDA) will meet tomorrow to discuss emergency use authorization of the Johnson & Johnson (J&J) COVID-19 vaccine candidate. If the vaccine is approved, Doctors Without Borders/Médecins Sans Frontières (MSF) calls on J&J to send its first shipments to COVAX for low- and middle-income countries, rather than high-income countries.